Seegene Inc, a South Korean provider of molecular diagnostics (MDx) solutions, announced on Friday that it has presented a conceptual video of its CURECA at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria, ahead of its anticipated debut in July.

The company said that industry professionals recognised CURECA as a promising advancement in automating the entire PCR diagnostic workflow -- from primary sample handling to result analysis. In response to the interest received, Seegene provided additional opportunities to showcase the solution at the ESCMID Global 2025.

Designed to automate the entire PCR diagnostic process, CURECA can handle various specimen types required in the pre-treatment stage in MDx -- such as stool, urine, blood, and sputum -- as well as perform the complete PCR testing workflow following sample loading.

The first component of CURECA is the Customizable Pre-treatment System (CPS), designed to automate the loading of primary sample tubes and operate pre-treatment processing.